AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34638151 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic dose (bemiparin 3,500 IU daily)
Number of subjects: 70
Study 34638151 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose bemiparin
Number of subjects: 70
Study 34638151 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic dose
Number of subjects: 70
Study 34638151 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 33646147 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted CSF Aβ
Number of subjects: 3146
Study 33646147 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted CSF p-tau
Number of subjects: 3146
Study 33646147 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted CSF t-tau
Number of subjects: 3146
Study 32325958 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified instructions
Number of subjects: 171
Study 32325958 — intervention group
Group type: COMPARATOR
Intervention: Standard manufacturer instructions
Number of subjects: 171
Study 35873779 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Bimanual Training (RBMT)
Number of subjects: 19
Study 35873779 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 19
Study 33833378 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI before starting AS
Number of subjects: 1286
Study 33833378 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI after being on AS
Number of subjects: 1286
Study 33833378 — intervention group
Group type: COMPARATOR
Intervention: No MRI
Number of subjects: 1286
Study 32228379 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 15
Study 32228379 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin
Number of subjects: 15
Study 32228379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 33675448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket compression device
Number of subjects: 108
Study 33675448 — intervention group
Group type: COMPARATOR
Intervention: Elastic adhesive tape
Number of subjects: 108
Study 34295702 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA + dynamic CT‐MPI
Number of subjects: 412
Study 34295702 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA + CT‐FFR
Number of subjects: 412
Study 32738875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical citicoline and vitamin B12 (Cit‐B12) 3 times daily for 18 months
Number of subjects: 30
Study 32738875 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times daily for 18 months
Number of subjects: 30
Study 35450755 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine-derived fibrin sealant (PFS) with dural sutures
Number of subjects: 200
Study 35450755 — intervention group
Group type: COMPARATOR
Intervention: Sutures alone
Number of subjects: 200
Study 32649851 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin Shin Jyutsu (JSJ) Self-Help educational intervention
Number of subjects: 41
Study 32649851 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 32396564 — intervention group
Group type: EXPERIMENTAL
Intervention: €15 voucher for a supermarket with the questionnaire
Number of subjects: 262
Study 32396564 — intervention group
Group type: COMPARATOR
Intervention: Control group (only received the questionnaire)
Number of subjects: 262
Study 32396564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 262
Study 32396564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (males)
Number of subjects: 262
Study 32396564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (females)
Number of subjects: 262
Study 34898320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (16 mg IV daily for 5 days followed by 8 mg daily for 5 days)
Number of subjects: 98
Study 34898320 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dexamethasone (6 mg IV daily for 10 days)
Number of subjects: 98
Study 34898320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 98
Study 34898320 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dexamethasone
Number of subjects: 98
Study 33611380 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy
Number of subjects: 0
Study 33611380 — intervention group
Group type: COMPARATOR
Intervention: Online discussion forum
Number of subjects: 0
Study 36375083 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral irrigation with 0.01% lidocaine (100 mg in 1 L normal saline)
Number of subjects: 94
Study 36375083 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 94
Study 35503346 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure with telemonitoring (n=1223)
Number of subjects: 2441
Study 35503346 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care alone (n=1218)
Number of subjects: 2441
Study 34895216 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERT intervention (multi-faceted health care system intervention including end-user participation, competency-based training, quality improvement, and empowerment of maternity unit leaders)
Number of subjects: 16
Study 34895216 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERT intervention components
Number of subjects: 16
Study 34895216 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERT intervention
Number of subjects: 16
Study 36036920 — intervention group
Group type: EXPERIMENTAL
Intervention: eCDS with the DEP
Number of subjects: 941
Study 36036920 — intervention group
Group type: COMPARATOR
Intervention: eCDS without the DEP (Control)
Number of subjects: 941
Study 34266897 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 20
Study 34266897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35291425 — intervention group
Group type: EXPERIMENTAL
Intervention: GL‐HOSVD denoising algorithm in DWI
Number of subjects: 210
Study 35291425 — intervention group
Group type: COMPARATOR
Intervention: Conventional DWI (control group)
Number of subjects: 210
Study 32746862 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention for adolescents with chronic conditions
Number of subjects: 0
Study 32746862 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for participation
Number of subjects: 0
Study 35417873 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH and class I obesity with comorbid COPD (Group 2)
Number of subjects: 49
Study 33185618 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 100
Study 33185618 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 33316444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic (CoC) THA
Number of subjects: 116
Study 33316444 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-conventional polyethylene (MoPc) THA
Number of subjects: 116
Study 35184887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric juice + brushing
Number of subjects: 5
Study 35184887 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva + brushing
Number of subjects: 5
Study 34184772 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg litoxetine
Number of subjects: 278
Study 34184772 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg litoxetine
Number of subjects: 278
Study 34184772 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg litoxetine
Number of subjects: 278
Study 34184772 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg litoxetine
Number of subjects: 278
Study 34184772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 32825977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fateh technique (16-min soft tissue manipulation for four weekly sessions)
Number of subjects: 52
Study 32825977 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (two daily exercises for four weeks)
Number of subjects: 52
Study 33690238 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with tamsulosin, dutasteride, and imidafenacin (TDI)
Number of subjects: 0
Study 32937232 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (with cocamidopropyl betaine) with an orange juice (OJ) rinse
Number of subjects: 18
Study 32937232 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (with cocamidopropyl betaine) with deionized (DI) water rinse
Number of subjects: 18
Study 32937232 — intervention group
Group type: COMPARATOR
Intervention: Comparator dentifrice (with sodium lauryl sulphate and tetrasodium pyrophosphate) with an OJ rinse
Number of subjects: 18
Study 32937232 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (with cocamidopropyl betaine) with an OJ rinse
Number of subjects: 18
Study 34041604 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ production of organic materials
Number of subjects: 124
Study 34041604 — intervention group
Group type: COMPARATOR
Intervention: Petroleum-originated contaminants
Number of subjects: 124
Study 34041604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial inputs
Number of subjects: 124
Study 34041604 — intervention group
Group type: COMPARATOR
Intervention: Allochthonous and petroleum-based inputs
Number of subjects: 124
Study 34296810 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza testing via PCR
Number of subjects: 1684
Study 34296810 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV testing via PCR
Number of subjects: 1684
Study 34296810 — intervention group
Group type: EXPERIMENTAL
Intervention: Household transmission of influenza
Number of subjects: 1684
Study 34296810 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PCR-confirmed influenza incidence
Number of subjects: 1684
Study 32493475 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg orally before bedtime for 12 weeks)
Number of subjects: 450
Study 32493475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical looking, orally before bedtime for 12 weeks)
Number of subjects: 450
Study 34699040 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Standard Treatment with Vitamin C
Number of subjects: 132
Study 34699040 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Standard Treatment with Alpha Lipoic Acid (ALA)
Number of subjects: 132
Study 34699040 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Standard Treatment with Vitamin C and Alpha Lipoic Acid (ALA)
Number of subjects: 132
Study 34699040 — intervention group
Group type: COMPARATOR
Intervention: Routine Standard Treatment (RST)
Number of subjects: 132
Study 34699040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 35603596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 234
Study 35603596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 32970395 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS‐FLU 372 μg
Number of subjects: 482
Study 32970395 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS‐FLU 186 μg
Number of subjects: 482
Study 32970395 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal steroid sprays
Number of subjects: 482
Study 32730284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian segmented regression model with informative prior distributions
Number of subjects: 25
Study 32730284 — intervention group
Group type: COMPARATOR
Intervention: Bayesian segmented regression model with minimally informative prior distributions
Number of subjects: 25
Study 32730284 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype P4285HX
Number of subjects: 25
Study 35429307 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention (matched savings accounts, mentorship, financial management, business development training)
Number of subjects: 702
Study 35429307 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention
Number of subjects: 702
Study 35429307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 702
Study 34411297 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical treatment network analysis
Number of subjects: 100000
Study 32571560 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOA)
Number of subjects: 900
Study 32571560 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 900
Study 32571560 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 900
Study 33588897 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH(SC) 60 IU/kg
Number of subjects: 126
Study 32039990 — intervention group
Group type: COMPARATOR
Intervention: apoB truncation
Number of subjects: 57973
Study 32039990 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 57973
Study 36409539 — intervention group
Group type: EXPERIMENTAL
Intervention: Keenoa
Number of subjects: 136
Study 36409539 — intervention group
Group type: COMPARATOR
Intervention: ASA24
Number of subjects: 136
Study 36409539 — intervention group
Group type: EXPERIMENTAL
Intervention: Keenoa and ASA24
Number of subjects: 136
Study 32068510 — intervention group
Group type: EXPERIMENTAL
Intervention: alfaxalone (5 mg/kg) and midazolam (0.5 mg/kg)
Number of subjects: 12
Study 32068510 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine (0.05 mg/kg) and midazolam (0.5 mg/kg)
Number of subjects: 12
Study 32068510 — intervention group
Group type: COMPARATOR
Intervention: flumazenil (0.05 mg/kg) alone or in combination with atipamezole (0.5 mg/kg)
Number of subjects: 12
Study 32068510 — intervention group
Group type: COMPARATOR
Intervention: plethysmography
Number of subjects: 12
Study 35247264 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (n = 1008)
Number of subjects: 2014
Study 35247264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1006)
Number of subjects: 2014
Study 35247264 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 2014
Study 32839967 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for conditional power estimation in CRTs with correlated interval-censored data.
Number of subjects: 0
Study 32839967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation studies to evaluate the proposed method.
Number of subjects: 0
Study 32839967 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the method on a large cluster-randomized HIV prevention trial.
Number of subjects: 0
Study 34651239 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous wound irrigation with 0.04% polyhexanide
Number of subjects: 456
Study 34651239 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous wound irrigation with 0.9% saline
Number of subjects: 456
Study 34651239 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SSI
Number of subjects: 456
Study 34651239 — intervention group
Group type: COMPARATOR
Intervention: Patients without SSI
Number of subjects: 456
Study 34096182 — intervention group
Group type: EXPERIMENTAL
Intervention: LungVision system for peripheral pulmonary nodule biopsy
Number of subjects: 63
Study 34096182 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy
Number of subjects: 63
Study 34096182 — intervention group
Group type: EXPERIMENTAL
Intervention: LungVision system
Number of subjects: 63
Study 34914889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg intravenously every 2 weeks)
Number of subjects: 743
Study 34914889 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 743
Study 34914889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 743
Study 34914889 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 743
Study 35575641 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 65
Study 32879983 — intervention group
Group type: EXPERIMENTAL
Intervention: Base diet consisting of the IAA provided at the RDA plus addition of individual DAAs to meet a 50:50 ratio of IAA:DAA on an N basis.
Number of subjects: 7
Study 32879983 — intervention group
Group type: COMPARATOR
Intervention: Diets corresponding to the amino acid pattern present in egg protein with all Glu and Gln present as Glu, or removed, with Ser used to make the diets isonitrogenous.
Number of subjects: 7
Study 34853360 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diode laser
Number of subjects: 42
Study 34853360 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 42
Study 32331433 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 28
Study 36066977 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (2 mg subcutaneously) once weekly for 26 weeks
Number of subjects: 127
Study 36066977 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (2 mg subcutaneously) once weekly for 26 weeks in a subgroup of obese patients
Number of subjects: 127
Study 36066977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 34931772 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group
Number of subjects: 24
Study 34931772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 34931772 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group (for STs with bone thickness > 0.5 mm)
Number of subjects: 24
Study 34931772 — intervention group
Group type: COMPARATOR
Intervention: Control group (for STs with bone thickness > 0.5 mm)
Number of subjects: 24
Study 35689257 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) for 8 weeks
Number of subjects: 0
Study 35689257 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33009192 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI‐PCA with target plasma concentrations between 0.8 and 10 ng/ml
Number of subjects: 50
Study 33009192 — intervention group
Group type: COMPARATOR
Intervention: PCA with bolus doses of 0.2 mg
Number of subjects: 50
Study 36096886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment during the postoperative period
Number of subjects: 0
Study 36096886 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise training
Number of subjects: 0
Study 34120336 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (3600 mg/day)
Number of subjects: 40
Study 34120336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35658544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 0
Study 35658544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham surgery with intermittent fasting and calorie restriction (SH-IF)
Number of subjects: 0
Study 35658544 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery ad libitum (SH-AL)
Number of subjects: 0
Study 34472893 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamiri-Digital (online single-session intervention for depression)
Number of subjects: 103
Study 33359134 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFM (Transit-Time Flow Measurement)
Number of subjects: 1568
Study 33359134 — intervention group
Group type: COMPARATOR
Intervention: Non-TTFM
Number of subjects: 1568
Study 33359134 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFM
Number of subjects: 1568
Study 34427047 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy for clinical high risk youth (FFT-CHR) - 18 1-hour sessions of family psychoeducation and communication/problem-solving skills training
Number of subjects: 220
Study 34427047 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care - 3 1-hour family psychoeducational sessions followed by 5 individual support sessions
Number of subjects: 220
Study 34541650 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary and diversified health education combined with personalized nutrition intervention
Number of subjects: 180
Study 34541650 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 180
Study 35843465 — intervention group
Group type: EXPERIMENTAL
Intervention: His Bundle Pacing (HBP)
Number of subjects: 50
Study 35843465 — intervention group
Group type: COMPARATOR
Intervention: Biventricular Pacing (BVP)
Number of subjects: 50
Study 34406128 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl Starch 130/0.4
Number of subjects: 135
Study 34406128 — intervention group
Group type: COMPARATOR
Intervention: 5% human albumin
Number of subjects: 135
Study 36066501 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injections, 50 units into both hands
Number of subjects: 90
Study 36066501 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections into both hands
Number of subjects: 90
Study 36066501 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injections
Number of subjects: 90
Study 36066501 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 90
Study 33839787 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (maximum 20 mg)
Number of subjects: 20
Study 33839787 — intervention group
Group type: COMPARATOR
Intervention: Prazosin GITS (maximum 30 mg)
Number of subjects: 20
Study 36113111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 469
Study 36113111 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 469
Study 32138661 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/L GO
Number of subjects: 0
Study 32138661 — intervention group
Group type: EXPERIMENTAL
Intervention: IAA (> 0.5 mg/L)
Number of subjects: 0
Study 32138661 — intervention group
Group type: EXPERIMENTAL
Intervention: GO and IAA cotreatment
Number of subjects: 0
Study 32138661 — intervention group
Group type: COMPARATOR
Intervention: GO alone
Number of subjects: 0
Study 32138661 — intervention group
Group type: EXPERIMENTAL
Intervention: GO treatment
Number of subjects: 0
Study 34501915 — intervention group
Group type: COMPARATOR
Intervention: Exergames training (ETG)
Number of subjects: 90
Study 34501915 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames combined with protein supplementation (ETPSG)
Number of subjects: 90